Iterum Therapeutics plc

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Show More...

  • Website http://www.iterumtx.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 1.00 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -1.77 -3.87 -8.82 -7.1 -6.74
    Dividends USD
    Payout Ratio % *
    Shares Mil 8.0 8.0 9.0 15.0 15.0
    Book Value Per Share * USD 6.56 -0.21 -2.81
    Free Cash Flow Per Share * USD -4.4 -5.82
    Return on Assets % -50.02 -79.83 -106.56 -166.85 -150.1
    Financial Leverage (Average) 1.19 1.18 1.37
    Return on Equity % -59.4 -94.61 -138.69 -454.48
    Return on Invested Capital % -59.4 -94.08 -110.18 -281.18 -321.68
    Interest Coverage -103.55 -178.77 -118.26 -28.29
    Current Ratio 6.13 6.2 7.61 0.32 0.61
    Quick Ratio 6.03 5.76 7.06 0.19 0.54
    Debt/Equity 0.18